INTRODUCTION
============

Polycystic kidney disease 2-like-1 (PKD2L1) has been reported to be regulated by extracellular and intracellular calcium although the response varies depending on different cell types and experiment conditions \[[@B1][@B2]\]. In our previous study, we have shown the different time courses of the channel activation and inactivation depending on different intracellular calcium concentrations \[[@B3]\]. The roles of PKD2L1 are found to be physiologically crucial for determining the intestinal orientation \[[@B4]\], regulating neuronal excitability \[[@B5]\], and maintaining spine curvature \[[@B6]\]. Along with other transient receptor potential (TRP) channels, the structure of PKD2L1 was also reported recently \[[@B7][@B8]\]. Although the studies unveil the significance of polycystin domain and the gating mechanisms of the channel, the N- and C-terminal regions were not structurally resolved. The flexibility of the terminal regions has been a barrier to understanding the functional domains of the channel including coiled-coil domain, EF-hand domain, oligomerization domain, and potentially, calmodulin binding domain. Calmodulin (CaM) is a calcium-binding, highly conserved protein and serves in regulation of a myriad of target proteins, among them being ion channels \[[@B9]\]. The two distinct lobes of CaM, acting as independent calcium sensors, and the long flexible linker in between allow CaM to have various conformations and effects on the target proteins. The CaM binding site has mostly been identified as the IQ motif or the modified, or a hydrophobic alpha helical sequence \[[@B10][@B11]\], but also varies depending on the channels.

Calmidazolium (CMZ), which is known as a CaM inhibitor \[[@B12]\], was used as an agonist of PKD2L1 \[[@B13]\]. We have also observed the agonistic effect of CMZ on the channel in the previous report \[[@B3]\]. However, the mechanism of how CMZ activates is unknown. Another CaM inhibitor known as *N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) is reported to bind to troponin C in the presence of calcium and inhibit striated muscle contraction. It also has nonspecific effects, such as blocking of L-type Ca^2+^, K^+^, Na^+^ channels, and sarcoplasmic reticulum calcium-release channels.

METHODS
=======

Cell culture and transient transfection
---------------------------------------

Human embryonic kidney 293 (HEK293) cells (American Type Culture Collection, Manassas, VA, USA) were cultured according to the supplier\'s recommendations. The cells were seeded in 12-well plates prior to transient transfection. The following day, 0.5 µg/well of internal ribosome entry site (IRES) and enhanced green fluorescence protein (EGFP) containing human PKD2L1 was transfected into cells using FuGENE 6 transfection reagent (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer\'s protocol. For 1 to 1 co-transfection with CaM, 0.5 µg/well of pCI-neomycin rat CaM was transfected into cells with human PKD2L1-IRES-EGFP, and for 2:1 co-transfection, 1 µg/well was transfected. Within 24 to 48 h, the attached cells were trypsinized and used for patch clamp recordings.

Electrophysiology
-----------------

Whole cell currents were recorded using an Axopatch 200B amplifier (Axon Instruments, Foster City, CA, USA). Currents were filtered at 5 kHz (−3 dB, 4-pole bessel), digitized using a Digidata 1440A Interface (Axon Instruments), and analyzed using a personal computer equipped with pClamp 10.2 software (Axon Instruments) and Origin software (Microcal origin v.8.0; Microcal Software, Northampton, MA, USA). Patch pipettes were made from borosilicate glass and had resistances of 2--3 MΩ when filled with pipette solutions. From holding potential at −60 mV, voltage ramp pulse was applied from −100 mV to 100 mV for 500 ms. For whole cell experiments, we used an external bath medium (standard bath solution) of the following composition (in mM): 150 NaCl, 10 *N*-(2-hydroxyethyl)piperazine-*N*′-2-ethansulfonic acid (HEPES), 1.8 CaCl~2~, and 1 MgCl~2~ with pH adjusted to 7.4 using NaOH. The pipette solutions contained (in mM): 100 CsMES, 35 NaCl, 10 HEPES, 5 cesium-1,2-bis-(2-aminophenoxy) ethane-*N*,*N*,*N*′,*N*′-tetraacetic acid (Cs-BAPTA), 2 MgCl~2~; 16 nM free \[Ca^2+^\], pH7.4. For recording the current responses of the channels to CaM inhibitors, 1 µM of CMZ (Calbiochem, San Diego, CA, USA) and 10 µM of W-7 (Sigma Aldrich, St. Loius, MO, USA) were used. The diluted solution was made on each day of experiment and any remainder of the solution was discarded after the experiment. Experiments were performed at room temperature (20℃--24℃).

Western blot
------------

Cells were plated in 6-well dishes. Lysates were prepared in lysis buffer (0.5% Triton X-100, 150 mM NaCl, 50 mM HEPES, 2 mM MgCl~2~, 2 mM EDTA, pH 7.4) via passage 10--15 times through a 26-gauge needle after sonication. After lysates were centrifuged at 13,000 ×g for 10 min at 4℃, the protein concentration in the supernatants was determined. The extracted proteins in sample buffer were loaded onto 10% Tris-glycine sodium dodecyl sulfate polyacrylamide gel electrophoresis gels. The proteins were transferred onto a polyvinylidene fluoride membrane. The membrane was incubated with anti-hemagglutinin (HA) (12CA5; Roche Molecular Biochemicals) and anti-β-tubulin (T-4026; Sigma Aldrich) overnight at 4℃.

Prediction of CaM binding site
------------------------------

The CaM binding site was predicted by Calmodulin Target Database (<http://calcium.uhnres.utoronto.ca/ctdb/ctdb/sequence.html>), using the protein sequence of human PKD2L1. The result is shown with numerical value. The series of 9 indicate highly significant position.

Statistics
----------

Results are presented as mean ± standard error of mean. The data were analyzed using Prism-GraphPad (GraphPad Software, San Diego, CA, USA). Statistical data were compared by paired or unpaired Student\'s t-test between two groups. The p \< 0.05 and p \< 0.01 were considered statistically significant. The number of whole cell recordings is indicated by n.

RESULTS
=======

PKD2L1 channel is activated by CaM inhibitors
---------------------------------------------

The PKD2L1 channel has been studied with many agonists among which CMZ is a potent activator of the homomeric channel. Although CMZ is used as an agonist of the PKD2L1 channel \[[@B1][@B3]\], the mechanism of its activating effect on the channel remains to be elucidated. To examine whether CMZ acts upon the channel mediated by CaM, we used W-7, which is also known as a CaM inhibitor. By performing whole-cell patch clamp on PKD2L1-expressed HEK293 cell, we observed the channel currents increased from 127 ± 35 pA/pF (n = 5) to 173 ± 45 pA/pF (n = 5) indicated in red ([Fig. 1](#F1){ref-type="fig"}).

PKD2L1 channel currents are reduced by CaM N-lobe
-------------------------------------------------

As we have observed the currents of the PKD2L1 channel increased by CMZ in our previous study \[[@B3]\] and W-7 in the present study, we came to a conclusion that the current increase of the channel is mediated by CaM. As expected, co-expression of PKD2L1 and CaM showed decreased basal currents, as well as decreased effect of CMZ. The I--V curve currents induced by CMZ are indicated in blue and the basal currents in black in [Fig. 2A--D](#F2){ref-type="fig"}. The basal currents of PKD2L1 co-expressed with CaM with 1 to 2 ratio were significantly decreased from 58 ± 9 pA/pF (n = 5) to 8 ± 2 pA/pF (n = 6) ([Fig. 2B, E](#F2){ref-type="fig"}) and with 1 to 1 ratio, from 69 ± 11 pA/pF (n = 6) to 29 ± 5 pA/pF (n = 5) ([Fig. 2G](#F2){ref-type="fig"}). The increased currents by CMZ, where the basal currents were subtracted from the CMZ-induced currents, were also reduced from 41 ± 11 pA/pF (n = 6) to 6 ± 5 pA/pF (n = 5) when co-expressed with 1 to 2 ratio ([Fig. 2B, F](#F2){ref-type="fig"}) and from 44 ± 8 pA/pF (n = 4) to 24 ± 11 pA/pF (n = 4) when co-expressed with 1 to 1 ratio ([Fig. 2H](#F2){ref-type="fig"}).

There are many studies regarding channel proteins that are regulated by CaM for which each lobe has an independent function \[[@B14][@B15][@B16]\]. To investigate whether each lobe has an independent effect on regulating the PKD2L1 channel, we co-expressed the channel with CaM deletion mutants. When co-expressed with CaMΔC with 1 to 2 ratio, the channel showed significant decrease in channel amplitudes to 13 ± 2 pA/pF (n = 6) ([Fig. 2C, E](#F2){ref-type="fig"}) and with 1 to 1 ratio, to 28 ± 7 pA/pF (n = 4) ([Fig. 2G](#F2){ref-type="fig"}). The increased currents by CMZ were also reduced to 14 ± 5 pA/pF (n = 6) when co-expressed with 1 to 2 ratio ([Fig. 2C, F](#F2){ref-type="fig"}) and to 14 ± 3 pA/pF (n = 4) when co-expressed with 1 to 1 ratio ([Fig. 2H](#F2){ref-type="fig"}). Interestingly, co-expression with CaMΔN did not alter the basal currents significantly, yielding 31 ± 11 pA/pF (n = 8) for 1 to 2 ratio expression ([Fig. 2D, E](#F2){ref-type="fig"}) and 98 ± 9 pA/pF (n = 6) for 1 to 1 ratio expression ([Fig. 2G](#F2){ref-type="fig"}). The increased currents by CMZ were significantly reduced to 12 ± 6 pA/pF (n = 8) for 1 to 2 ratio expression ([Fig. 2D, F](#F2){ref-type="fig"}) and to 44 ± 10 pA/pF (n = 4) for 1 to 1 ratio expression ([Fig. 2H](#F2){ref-type="fig"}). These results suggest that the PKD2L1 channel is regulated and inhibited by CaM and specifically by the N-lobe.

Intracellular calcium in the presence of CaM delays the time course of the channel potentiation
-----------------------------------------------------------------------------------------------

In our previous study, we have shown the different time courses of the channel potentiation and inactivation under different intracellular calcium concentration \[[@B3]\]. Since CaM is a calciumregulated protein, we examined whether changes in intracellular calcium concentration alter the potentiation and inactivation characteristics of the channel when co-expressed with CaM. Surprisingly, in the presence of over-expressed CaM, the peak currents of the channel with 16 nM and 100 nM free Ca^2+^ was significantly reduced from 175 ± 37 pA/pF (n = 10) to 18 ± 5 pA/pF (n = 4) and from 301 ± 50 pA/pF (n = 5) to 55 ± 27 pA/pF (n = 5), respectively ([Fig. 3G](#F3){ref-type="fig"}). However, the potentiation time of the channel with 16 nM free Ca^2+^ showed no significant difference, yielding 405 ± 56 sec (n = 8) for PKD2L1 and 395 ± 43 sec (n = 4) for CaM co-expression ([Fig. 3H](#F3){ref-type="fig"}). With 100 nM free Ca^2+^, the potentiation time of the channel increased from 218 ± 38 sec (n = 5) to 503 ± 47 sec (n = 4) ([Fig. 3H](#F3){ref-type="fig"}). With 500 nM free Ca^2+^, there was no significant change in the peak currents and the potentiation time, yielding from 93 ± 22 pA/pF (n = 9) to 114 ± 45 pA/pF (n = 4) and from 124 ± 39 sec (n = 9) to 183 ± 49 sec (n = 4), respectively ([Fig. 3G, H](#F3){ref-type="fig"}).

Putative CaM-binding domain is crucial for PKD2L1 channel functionality
-----------------------------------------------------------------------

To investigate the binding domain of CaM in PKD2L1, we used Calmodulin Target Database with the protein sequence of human PKD2L1. The result shows that the protein sequences from K590 to E600 are highly significant region for CaM binding ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}). Based on this result, we generated PKD2L1 mutants where selective amino acids were deleted or substituted with alanine or truncated \[[@B10]\]. As shown in [Fig. 4C](#F4){ref-type="fig"} and [Supplementary Fig. 2A--D](#S2){ref-type="supplementary-material"}, Δ590--600, L592/597E, RRRK/AAAA, and 588Stop mutants lost PKD2L1 characteristics of I--V curve, exhibiting significant reduction in channel activity to 9 ± 1 pA/pF (n = 7), 13 ± 3 pA/pF (n = 13), 11 ± 1 pA/pF (n = 12), and 11 ± 1 pA/pF (n = 4), respectively. While the mutants had no response to CMZ, they showed increased currents induced by 100 µM of 8-Br-cAMP treatment ([Supplementary Fig. 2E, F](#S2){ref-type="supplementary-material"}). We observed that the channel characteristics of 600Stop and 608Stop truncation mutants were intact and the currents were increased by CMZ from 27 ± 8 pA/pF (n = 5) to 51 ± 11 pA/pF (n = 5) ([Fig. 4A](#F4){ref-type="fig"}) and from 87 ± 16 pA/pF (n = 4) to 166 ± 40 pA/pF (n = 4) ([Fig. 4B](#F4){ref-type="fig"}), respectively. The baseline currents are indicated in black and CMZ-induced currents in blue in [Fig. 4](#F4){ref-type="fig"}. Surprisingly, the basal currents of 608Stop were significantly increased while 600Stop showed similar basal currents with that of PKD2L1^WT^ ([Fig. 4C](#F4){ref-type="fig"}). To examine the expression pattern of each mutant, we performed Western blot analysis with HA antibodies using lysates of HEK293 cells expressing human PKD2L1 ([Fig. 4D](#F4){ref-type="fig"}). The result showed that the expression of PKD2L1^WT^ (92 kDa), L592/597E (92 kDa), RRRK/AAAA (92 kDa; R594A, R596A, R598A, R599A), Δ590--600 (90.6 kDa) and 600Stop (68.8 kDa) did not differ greatly, but the expression level of 608Stop (69.8 kDa) was greatly reduced.

To examine the phenomenon of increased currents in 608Stop mutant, we generated EF-hand deletion mutant (ΔEF). The peak currents of the ΔEF mutant channel with 16 and 500 nM free Ca^2+^ showed significant increases yielding 481 ± 89 pA/pF (n = 6) and 373 ± 63 pA/pF (n = 5), respectively ([Fig. 5A, C, D](#F5){ref-type="fig"}). However, the peak currents and the potentiation time of the mutant channel with 100 nM free Ca^2+^ showed no significant difference yielding 291 ± 57 pA/pF (n = 4) and 223 ± 53 sec (n = 4), respectively ([Fig. 5B, D, E](#F5){ref-type="fig"}). The potentiation time of ΔEF mutant channel with 16 nM free Ca^2+^ was significantly reduced yielding 222 ± 33 sec (n = 5) and increased with 500 nM calcium yielding 280 ± 32 sec (n = 5) ([Fig. 5A, C, E](#F5){ref-type="fig"}).

DISCUSSION
==========

Since our previous study, we have used CMZ as an agonist of PKD2L1 channel. Knowing that CMZ is an inhibitor of CaM, we were interested to investigate on the relationship between CaM protein and the channel. To verify that the activation of the channel is mediated by the inhibition of CaM, we used another CaM inhibitor, W-7, which has a similar property to that of CMZ ([Fig. 1D](#F1){ref-type="fig"}). They are both membrane-permeable amphipathic weak bases. Since W-7 inhibits CaM by blocking the hydrophobic binding pocket of the protein with the aromatic rings \[[@B17]\], we can infer the similar blocking mechanism for CMZ. As expected, W-7 significantly increased the currents of the PKD2L1 channel, supporting that CMZ- or W-7-induced activation of the channel is mediated by CaM. In agreement with the result, co-expression with CaM significantly reduced the channel currents. To examine whether each lobe of CaM takes different roles, we have used CaMΔC and CaMΔN. Interestingly, only CaMΔC significantly reduced basal currents of the channel while CaMΔN did not alter the current amplitudes. To reinforce reliability cause, we had two different DNA ratios for transfection: one set is transfected with equal amounts of PKD2L1 and CaM DNA and the other set is with a 1 to 2 ratio. These results suggest that the binding mechanism is similar to that of voltage-gated sodium (Na~v~) and small-conductance Ca^2+^-activated K^+^ (SK) channel \[[@B15][@B16]\].

CaM has been studied extensively as one of the important modulators of ion channels \[[@B9][@B14][@B15][@B16][@B18][@B19][@B20][@B21]\]. One of many structural studies of ion channel elaborates the regulation of Na~v~ channel by interaction with Ca^2+^/CaM at C-terminal domain (CTD) \[[@B16]\]. The study suggests that CaM binds to IQ domain of CTD. For both Na~v~1.2 and Na~v~1.5, the channel binds to C-lobe of CaM in the absence of calcium, whereas in the presence of calcium, the channel binds to both lobes of CaM. The study also reports that there were only minor conformational changes to "semi-open" form caused by the binding of C-lobe in the presence of calcium. As expected from CaM C-lobe binding to the channel, the C-lobe has lower affinity to calcium ions than that of N-lobe. The CaM protein is known to have higher affinity to Ca^2+^ ions in its C-lobe, but the binding to a target protein reduces the affinity in the Na~v~ channel. The subsequent binding of CaM N-lobe, which is fully occupied with calcium ions, gives "closed" conformational changes of the channel. The regulation of a SK channel by CaM binding has been studied by electrophysiology and structural analyses \[[@B15][@B22]\]. The results elucidate the mechanism where the C-lobe of CaM is constitutively bound to the channel in the absence of calcium and in the presence of calcium, the N-lobe rearranges its structure to a more open conformation, then binding to the channel. The distinct difference in the roles of N- and C-lobe of CaM and the binding mechanism may be similar to that of the Na~v~ channel. SK channel is rather opened and activated by the binding of N-lobe CaM while Na~v~ channel is closed and inactivated. The results we have observed in the present study, where coexpression with CaM or CaMΔC reduced the channel currents, support the mechanism similar to that of the Na~v~ channel.

For it is well-known that CaM is a calcium binding protein, we also examined the channel response to different free calcium concentrations when co-expressed with CaM. Surprisingly, the channel currents were significantly reduced with 16 and 100, but not with 500 nM free Ca^2+^ ([Fig. 3G](#F3){ref-type="fig"}). The potentiation time of the channel with 100 nM free calcium was increased ([Fig. 3H](#F3){ref-type="fig"}). Along with the results from [Fig. 5D](#F5){ref-type="fig"} where the ΔEF mutant currents were increased with 16 and 500 but not with 100 nM free Ca^2+^, we suggest that both CaM and EF-hand take part in regulating the channel but with different calcium affinities. The actions of calcium on CaM and EF-hand in a channel protein has been studied suggesting that Ca^2+^/CaM releases the binding domain of the channel and let Ca^2+^/EF-hand interact with the domain \[[@B23][@B24]\]. We suggest that in the absence of calcium, EF-hand constantly binds and constantly exerts inhibitory effects on the channel ([Fig. 6A](#F6){ref-type="fig"}), but in the presence of calcium, it releases while CaM binds and inhibits the channel activity ([Fig. 6B](#F6){ref-type="fig"}). At higher concentration or 500 nM free Ca^2+^, Ca^2+^/CaM loses affinity to the channel and Ca^2+^/EF-hand binds to the CaM binding domain, inhibiting the channel ([Fig. 6D](#F6){ref-type="fig"}). An alignment of the protein sequences of the channel and EF-hand domains of CaM ([Fig. 7A](#F7){ref-type="fig"}) demonstrates higher similarity of CaM (EF2) to the channel supporting the competing mechanism of CaM N-lobe and EF-hand domain of the channel. The fact that the protein sequences of CaM binding domain and EF-hand domain in PKD2L1 are also conserved in PKD2 with high similarity further accentuates the importance of our findings in this study ([Fig. 7B, C](#F7){ref-type="fig"}).

The EF-hand domain is located at 633--668 (human) and earlier found to be not related to calcium-induced activation of the channel \[[@B1]\]. Although not thoroughly explained, the report also shows increased and rather unstable currents of the EF-hand truncation mutant. In this study, we observed significant changes in current amplitudes and potentiation time in ΔEF mutant channel with adjusted calcium concentrations.

To investigate the CaM-binding domain within the channel, we used Calmodulin Target Database that provides a prediction program. As a result, the putative binding domain was located at the C-terminal region of the channel from K590 to E600. Consequently, the mutants were generated based on the report from Zhu \[[@B10]\]. Although we expected that CaM would not be able to bind to the mutants thereby increasing the currents, the results demonstrated a loss of functionality for each mutant except for 600Stop and 608Stop. One possible explanation for this is that the putative CaM-binding domain may contain other functional domains \[[@B25]\]. One report suggests that the region that overlaps with the putative CaM domain ([Fig. 4E](#F4){ref-type="fig"}) is responsible for strong homomerization of the channel. However, this view has recently been challenged by studies by cryo-EM where the truncated constructs were structurally stable \[[@B7][@B8][@B26]\]. We suggest that the region is responsible for interaction with other domains of the channel to form a proper binding domain for CaM.
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SUPPLEMENTARY MATERIALS
=======================

Supplementary data including two figures can be found with this article online at <http://pdf.medrang.co.kr/paper/pdf/Kjpp/Kjpp2019-23-03-06-s001.pdf>.

###### Supplementary Fig. 1

**The identification of the putative calmodulin (CaM)-binding domain region at KTLLRLRLRKE (590--600) with higher scores.** The putative binding domain was predicted and analyzed by Calmodulin Target Database with protein sequences of human polycystic kidney disease 2-like-1.

###### Supplementary Fig. 2

**The loss of channel function in the putative calmodulin (CaM)-binding domain mutants.** (A) A full current trace of polycystic kidney disease 2-like-1 (PKD2L1)(Δ590--600) mutant (*left*) and the I--V relationship (*right*). (B) A full current trace of PKD2L1(L592/597E) mutant (*left*) and the I--V relationship (*right*). (C) A full current trace of PKD2L1(RRRK/AAAA) mutant (*left*) and the I--V relationship (*right*). (D) A full current trace of PKD2L1(588Stop) mutant (*left*) and the I--V relationship (*right*). (E) A full current trace of PKD2L1(L592/597E) mutant (*left*) and the I--V relationship (*right*). The currents induced by cyclic-adenosine monophosphate (cAMP) is indicated in red. (F) A full current trace of PKD2L1(RRRK/AAAA) mutant (*left*) and the I--V relationship (*right*). The currents induced by cAMP is indicated in red.

![The effect of W-7 on polycystic kidney disease 2-like-1 (PKD2L1) current.\
(A) A full current trace of PKD2L1 activation induced by 10 µM of *N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) measured in a PKD2L1-expressed human embryonic kidney 293 cell using whole-cell patch clamp technique. From the holding potential at −60 mV, ramp pulse was applied from −100 mV to 100 mV. (B) The current (I)--voltage (V) relationship of PKD2L1. The I--V curve demonstrates outward rectification of the channel. Each colored line indicates I--V relationship at the basal current amplitude (*black*) and at the application of W-7 (*red*), respectively. (C) A summarized current amplitude of PKD2L1 induced by W-7. (D) Molecular structures of CMZ and W-7. They are both amphipathic weak bases. ^\*\*^p \< 0.01.](kjpp-23-219-g001){#F1}

![The effect of co-expression with calmodulin (CaM) and its deletion mutants on polycystic kidney disease 2-like-1 (PKD2L1) current.\
(A) A full current trace of PKD2L1 (*left*) activated by 1 µM of calmidazolium (CMZ) and the I--V relationship of PKD2L1 (*right*) at the basal current amplitude (*black*) and at the application of 1 µM of CMZ (*blue*). (B) A full current trace (*left*) and I--V relationship (*right*) of PKD2L1, co-expressed with CaM with 1:2 ratio, activated by CMZ. Blue line indicates I--V relationship at the application of CMZ. (C) A full current trace (*left*) and I--V relationship (*right*) of PKD2L1, co-expressed with CaMΔC with 1:2 ratio, activated by CMZ. Blue line indicates I--V relationship at the application of CMZ. (D) A full current trace (*left*) and I--V relationship (*right*) of PKD2L1, co-expressed with CaMΔN with 1:2 ratio, activated by CMZ. Blue line indicates I--V relationship at the application of CMZ. (E) A summarized basal current amplitude of PKD2L1, PKD2L1 with CaM, PKD2L1 with CaMΔC, and PKD2L1 with CaMΔN with 1:2 expression ratio. (F) A summarized increased current amplitude of CMZ-induced PKD2L1, PKD2L1 with CaM, PKD2L1 with CaMΔC, and PKD2L1 with CaMΔN with 1:2 expression ratio. (G) A summarized basal current amplitude of PKD2L1, PKD2L1 with CaM, PKD2L1 with CaMΔC, and PKD2L1 with CaMΔN with 1:1 expression ratio. (H) A summarized increased current amplitude of CMZ-induced PKD2L1, PKD2L1 with CaM, PKD2L1 with CaMΔC, and PKD2L1 with CaMΔN with 1:1 expression ratio. ^\*^p \< 0.05, ^\*\*\*^p \< 0.001.](kjpp-23-219-g002){#F2}

![The potentiation and inactivation of the channel with over-expression of calmodulin (CaM) under different intracellular free calcium concentrations.\
(A) A full current trace of polycystic kidney disease 2-like-1 (PKD2L1) measured under 16 nM free calcium condition. (B) A full current trace of PKD2L1 measured under 100 nM free calcium condition. (C) A full current trace of PKD2L1 measured under 500 nM free calcium condition. (D) A full current trace of PKD2L1 measured under 16 nM free calcium condition in a PKD2L1- and CaM-expressed human embryonic kidney 293 (HEK293) cell. (E) A full current trace of PKD2L1 measured under 100 nM free calcium condition in a PKD2L1- and CaM-expressed HEK293 cell. (F) A full current trace of PKD2L1 measured under 500 nM free calcium condition in a PKD2L1- and CaM-expressed HEK293 cell. (G) A summarized peak current of PKD2L1 and the channel co-expressed with CaM under 16, 100, 500 nM free Ca^2+^ condition. (H) A summarized peak time of PKD2L1 and the channel co-expressed with CaM under 16, 100, 500 nM free Ca^2+^ condition. ^\*^p \< 0.05, ^\*\*^p \< 0.01.](kjpp-23-219-g003){#F3}

![The loss of function in the putative calmodulin (CaM)-binding domain mutants.\
(A) A full current trace (*left*), I--V relationship (*middle*), and a summarized current amplitude (*right*) of polycystic kidney disease 2-like-1 (PKD2L1)600Stop activated by calmidazolium (CMZ) (*blue*). (B) A full current trace (*left*), I--V relationship (*middle*), and a summarized current amplitude (*right*) of PKD2L1608Stop activated by CMZ (*blue*). (C) A summarized basal current of PKD2L1 and its mutants. (D) The expression pattern of PKD2L1 and its mutants analyzed by Western blotting. (E) Protein sequence between 588 and 608 where functional domains are located. WT, wild type; OD, oligomerization domain; IB, immunoblot. ^\*^p \< 0.05, ^\*\*^p \< 0.01, ^\*\*\*^p \< 0.001.](kjpp-23-219-g004){#F4}

![The potentiation and inactivation of the polycystic kidney disease 2-like-1 (PKD2L1)ΔEF mutant channel under different intracellular free calcium concentration.\
(A) A full current trace of PKD2L1 (*gray*) and ΔEF mutant (*blue*) measured under 16 nM free calcium condition. (B) A full current trace of PKD2L1 (*gray*) and ΔEF mutant (*red*) measured under 100 nM free calcium condition. (C) A full current trace of PKD2L1 (*gray*) and ΔEF mutant (*green*) measured under 500 nM free calcium condition. (D) A summarized peak current of PKD2L1 and ΔEF mutant with 16, 100, 500 nM free Ca^2+^. (E) A summarized peak time of PKD2L1 and ΔEF mutant with 16, 100, 500 nM free Ca^2+^. WT, wild type. ^\*^p \< 0.05, ^\*\*^p \< 0.01, ^\*\*\*^p \< 0.001.](kjpp-23-219-g005){#F5}

![A schematic drawing of the predicted mechanism by which calmodulin (CaM) regulates polycystic kidney disease 2-like-1 channel.\
(A) Under 0 nM or basal levels of calcium (*blue*), EF-hand (*yellow*) binds to the channel, constantly inhibiting and CaM remains bound to the channel exerting weak inhibition. The CaM binding peptide is indicated with a color gradient where N-terminus is colored in blue and C-terminus in red. (B) As the calcium levels rise, the EF-hand binds to calcium releasing the channel thereby promoting channel potentiation and CaM C-lobe (*green*) remains bound to the channel. (C) As the concentration of internal calcium reaches to 100 nM, both inhibition by CaM N-lobe (orange) and potentiation by release of EF-hand are exerted on the channel. (D) At higher concentration of calcium, EF-hand that has similar protein sequence to the N-lobe of CaM binds to the channel competing against the N-lobe of CaM.](kjpp-23-219-g006){#F6}

![Protein sequence alignment of polycystic kidney disease 2-like-1 (PKD2L1) with PKD2 and EF-hand domains of calmodulin (CaM).\
(A) An alignment of PKD2L1 and CaM EF-hand domains with identical residues indicated in red. (B) An alignment of the PKD2L1 and PKD2 CaM binding domain (BD) with identical residues indicated in red. (C) An alignment of the PKD2L1 and PKD2 EF-hand domain with identical residues indicated in red.](kjpp-23-219-g007){#F7}
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